Summary
Cannot be evaluated against the provided FDA label excerpt because the prompt includes multiple claims but the evaluation content supplied does not provide label-text coverage for key assertions (e.g., “non-opioid,” “up to 72 hours,” pricing amounts, patent expiration, and opioid-reduction design). This prevents determining support/contradiction/omission for most claims.
Category Scores
Accurate Statements
Unsupported Statements
Exparel is a non-opioid local anesthetic.
The provided label excerpt does not state “non-opioid” or address opioid status.
Exparel provides post-surgical pain relief for up to 72 hours after a single administration.
The provided excerpt does not state “up to 72 hours” post-surgical pain relief after a single administration.
Exparel works by encapsulating the anesthetic bupivacaine in a liposome.
The provided description states multivesicular liposomes containing bupivacaine, but the prompt’s excerpt does not explicitly phrase this as “encapsulating…in a liposome” (cannot confirm exact claim wording from provided text).
Exparel slowly releases bupivacaine over time, prolonging its effect.
The excerpt states bupivacaine is released from multivesicular liposomes, but it does not state “slowly releases…prolonging its effect” in the provided sections.
This mechanism is designed to reduce the need for opioid pain medication after surgery.
The provided excerpt does not discuss opioid reduction or prescribing behavior.
In a hospital outpatient setting, the average Medicare-approved amount for Exparel was $323.33 in 2023.
The provided label excerpt contains no pricing or reimbursement data.
In a hospital outpatient setting, the average out-of-pocket cost for Exparel beneficiaries was $50 in 2023.
The provided label excerpt contains no pricing or reimbursement data.
In an ambulatory surgical center, the average Medicare-approved amount for Exparel was $416.91 in 2023.
The provided label excerpt contains no pricing or reimbursement data.
In an ambulatory surgical center, the average out-of-pocket cost for Exparel beneficiaries was $65 in 2023.
The provided label excerpt contains no pricing or reimbursement data.
Exparel's price can vary depending on the healthcare setting and the specific dosage administered.
The provided label excerpt contains no statements about price variability by setting or dosage.
The cost of Exparel is influenced by the formulation and dosage used.
The provided label excerpt contains no statements about cost drivers.
The cost of Exparel is influenced by the specific medical procedure it is administered with.
The provided label excerpt contains no statements about cost drivers.
The cost of Exparel is influenced by the pricing strategies of its manufacturer, Pacira BioSciences.
The provided label excerpt contains no manufacturer pricing-strategy statements.
Exparel's extended-release mechanism contributes to its cost compared to traditional local anesthetics.
The provided label excerpt does not discuss pricing relative to other anesthetics or cost determinants.
The original patent for Exparel was set to expire in 2026.
The provided label excerpt does not discuss patent dates.
Contradictions
Important Omissions
Whether the claims align with labeled indications, administration routes, and dosing cannot be fully assessed because the prompt’s provided label excerpt lacks the sections needed to verify several claims (e.g., the basis for “up to 72 hours,” dosing instructions, and any language addressing opioid need).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims cannot be supported by the provided label excerpt (e.g., duration of post-surgical pain relief, opioid-reduction design). Unsupported medication-duration or analgesic-trajectory claims could mislead use expectations relative to labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA label excerpt (notably opioid-related assertions, duration “up to 72 hours,” and all reimbursement/patent/cost statements).
Suggested Improvement
Limit statements to what is explicitly supported in the provided label sections (e.g., EXPAREL contains bupivacaine in multivesicular liposomes and is for infiltration or perineural use; labeled indications by route and age). Remove or qualify unsupported claims (duration, opioid reduction, pricing, patent expiration).